Why Did Plus Therapeutics (PSTV) Soar 36.24% Pre-Market After Earnings Miss?

Plus Therapeutics (NASDAQ:PSTV) reported a significant increase of 36.24% in pre-market trading on June 2, 2025.

Plus Therapeutics reported a quarterly loss of $1.19 per share, which fell short of the analyst consensus estimate of $0.25 by 376%. The company's first-quarter loss amounted to $17.4 million, reflecting a challenging period for the biotechnology firm. The earnings miss was substantial, with the GAAP EPS of -$1.19 missing the estimate by $0.97. Despite the financial setback, the company's revenue for the quarter was $1.06 million, indicating some level of operational activity.

This earnings report has likely contributed to the significant pre-market surge in Plus Therapeutics' stock price, as investors react to the company's financial performance and future prospects. The substantial earnings miss and the resulting financial loss have raised concerns about the company's ability to meet market expectations and sustain its operations. However, the pre-market rally suggests that some investors may be betting on a turnaround or potential future developments that could improve the company's financial outlook.